23andMe FDA flap just a bump in the road say investors

When the Food and Drug Administration told personal-genetics company 23andMe in November to stop sending consumers detailed information about their DNA, some industry watchers said the move could devastate an emerging area of medicine that holds promise for better health outcomes.

But it was more of a flesh wound, said Claremont Creek Ventures Director Ted Driscoll. Though not an investor in 23andMe, he has two genetics-testing companies in his portfolio.

23andMe, a Google-backed startup that offers consumers reams of genetic information after analyzing a saliva sample for $99, may be sidelined for a while, Dr. Driscoll said. But the company will likely rebound after a few tweaks to its business model, and other DNA-testing startups will keep moving forward in the meantime.

Read the full, original story: 23andMe Flap With FDA Just a Bump in the Road, One Genetics-Testing Investor Says

Outbreak
Outbreak Daily Digest
Biotech Facts & Fallacies
Genetics Unzipped
Infographic: How dangerous COVID mutant strains develop

Infographic: How dangerous COVID mutant strains develop

Sometime in 2019, probably in China, SARS CoV-2 figured out a way to interact with a specific "spike" on the ...
Untitled

Philip Njemanze: Leading African anti-GMO activist claims Gates Foundation destroying Nigeria

Nigerian anti-GMO activist, physician, and inventor pushes anti-gay and anti-GMO ...

Most Popular

News on human & agricultural genetics and biotechnology delivered to your inbox.
glp menu logo outlined

Newsletter Subscription

Optional. Mail on special occasions.
Send this to a friend